We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Read MoreHide Full Article
Amicus Therapeutics, Inc.’s (FOLD - Free Report) lead drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.
Sales of Galafold have been rising consistently over the past years. In the first nine months of 2023, the drug generated sales worth $281.2 million, increasing 16.6% on a year-over-year basis. Galafold is currently approved in several countries, including the United States, European Union (EU), United Kingdom and Japan.
In 2021, Galafold received label expansion in the EU for long-term treatment of adolescents aged 12 years and older with Fabry disease. Such label expansion, along with approvals in additional geographies, is likely to drive sales of the drug further in 2024 and beyond.
Shares of Amicus have gained 18.9% in the past year against the industry’s decline of 14.1%.
Image Source: Zacks Investment Research
In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults, who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.
The FDA nod was based on positive data from the phase III PROPEL study, the only randomized and controlled trial in LOPD.
Earlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults. Global launches of Pombiliti and Opfolda are currently underway, including the United States, EU and United Kingdom.
The recent approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024 and beyond.
Though Amicus is riding on the success of Galafold, which drives the majority of the company’s top line, heavy dependence on the product for revenues remains a concern. Any regulatory setback for the drug will hurt the company’s growth prospects.
Also, several large pharmaceutical and biotechnology companies currently market and sell products for treating Fabry disease and Pompe disease. This acute competition remains a headwind for Amicus in the days ahead.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 43.8%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have gained 21.4%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining one occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have gained 2.8%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining one occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Amicus Therapeutics, Inc.’s (FOLD - Free Report) lead drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.
Sales of Galafold have been rising consistently over the past years. In the first nine months of 2023, the drug generated sales worth $281.2 million, increasing 16.6% on a year-over-year basis. Galafold is currently approved in several countries, including the United States, European Union (EU), United Kingdom and Japan.
In 2021, Galafold received label expansion in the EU for long-term treatment of adolescents aged 12 years and older with Fabry disease. Such label expansion, along with approvals in additional geographies, is likely to drive sales of the drug further in 2024 and beyond.
Shares of Amicus have gained 18.9% in the past year against the industry’s decline of 14.1%.
In September 2023, the FDA approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) 65mg capsules, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults, who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.
The FDA nod was based on positive data from the phase III PROPEL study, the only randomized and controlled trial in LOPD.
Earlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults. Global launches of Pombiliti and Opfolda are currently underway, including the United States, EU and United Kingdom.
The recent approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024 and beyond.
Though Amicus is riding on the success of Galafold, which drives the majority of the company’s top line, heavy dependence on the product for revenues remains a concern. Any regulatory setback for the drug will hurt the company’s growth prospects.
Also, several large pharmaceutical and biotechnology companies currently market and sell products for treating Fabry disease and Pompe disease. This acute competition remains a headwind for Amicus in the days ahead.
Amicus Therapeutics, Inc. Price and Consensus
Amicus Therapeutics, Inc. price-consensus-chart | Amicus Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Amicus currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 43.8%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have gained 21.4%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining one occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have gained 2.8%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining one occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.